Topics:

Onyx and Eli Lilly Expand Their Research Alliance on BRCA1

Onyx and Eli Lilly Expand Their Research Alliance on BRCA1

RICHMOND, Ca--Onyx Pharmaceuticals has announced an extension and expansion of its research alliance with Eli Lilly focusing on BRCA1, the gene linked to increased risk of breast and ovarian cancer. Lilly has exclusive rights to the BRCA1 gene by license from Myriad Genetics, Inc.

The collaboration, originally begun in May 1995, aims to understand the role of BRCA1-related pathways in breast cancer and to identify proteins that interact with the gene that could be used to develop therapeutics.

 
Loading comments...
Please Wait 20 seconds or click here to close